Streetbeat News

MIRA

MIRA Pharmaceuticals, Inc.

Industry

Drug Manufacturers - General

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Open

1.28

Mkt cap

21M

Volume

357K

High

1.33

P/E Ratio

-2.40

52-wk high

5.01

Low

1.23

Div yield

N/A

52-wk low

0.51

In Thursday's intraday session, several healthcare stocks experienced significant movements. Onconetix (ONCO) saw a 161.5% rise, while Processa Pharma (PCSA) increased by 98.04%. Acutus Medical (AFIB) and Vera Therapeutics (VERA) also saw substantial gains. Conversely, Redhill Biopharma (RDHL) and Nuwellis (NUWE) were among the notable losers, with declines of 47.6% and 15.2%, respectively. Humana (HUM) also declined by 12.06% after releasing Q4 earnings.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:31 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Sera Prognostics (SERA) saw a massive increase of 231.9%, while OptiNose (OPTN) led the decliners with a 22.4% drop. Other notable gainers include Phio Pharma (PHIO), Syros Pharmaceuticals (SYRS), Altimmune (ALT), Arvinas (ARVN), and Altamira Therapeutics (CYTO). On the losing side were Mira Pharmaceuticals (MIRA), InVivo Therapeutics Hldg (NVIV), Allarity Therapeutics (ALLR), GlucoTrack (GCTK), and Sonoma Pharmaceuticals (SNOA).

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:31 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. EyePoint Pharmaceuticals (EYPT) saw a dramatic increase of 378.8%, while Alterity Therapeutics (ATHE) and Lucy Scientific Discovery (LSDI) also posted substantial gains. On the downside, NexImmune (NEXI) and Panbela Therapeutics (PBLA) experienced notable declines, along with other companies such as Sana Biotechnology (SANA) and Vivos Therapeutics (VVOS).

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 1:06 pm

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) has announced promising results from AI simulations for MIRA1a, a potential treatment for anxiety, appetite, and cognition issues. The simulations, conducted with InSilicoTrials, suggest MIRA1a's advantages over THC, including fewer side effects. MIRA1a targets specific brain receptors and may offer superior anti-anxiety effects, appetite suppression, and cognitive enhancement. The company is working towards an IND Application with the FDA, positioning MIRA1a as a significant development in neuropharmacology.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 1:03 pm

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced that its product Ketamir-2, an oral formulation for depression treatment, has a predicted oral bioavailability of 80%. This is significantly higher than the current oral or intranasal absorption of ketamine. The company's lead developer highlighted the potential for Ketamir-2 to offer ease of administration and fewer side effects. IQVIA's analysis predicts that Ketamir-2 could generate an average annual sales of $3 billion by 2035, addressing the therapeutic gap in treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI). MIRA Pharmaceuticals is advancing clinical development and focusing on confirming the safety and efficacy of Ketamir-2.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:11 pm

Anavex Life Sciences Corp. (AVXL) shares dropped by 10% after reporting a Q4 net loss of $10.1 million, or 12 cents per share, compared to a net loss of $14.3 million, or 18 cents per share, in the same period last year. Other stocks experienced significant movements in Monday's mid-day session, with notable gainers including RedHill Biopharma Ltd. (RDHL), Biodexa Pharmaceuticals Plc (BDRX), and Tharimmune, Inc. (THAR), among others. Losers included 10X Capital Venture Acquisition Corp. II (VCXA), BioNexus Gene Lab Corp. (BGLC), and HCW Biologics Inc. (HCWB). Affirm Holdings, Inc. (AFRM) saw a jump of 13.7% following positive 'buy now, pay later' predictions for Cyber Monday.

Portfolio Pulse from Lisa Levin

November 27, 2023 | 6:41 pm

Health care stocks experienced significant movement in Monday's intraday session. Redhill Biopharma (RDHL) led the gainers with a 207.0% increase, while Harpoon Therapeutics (HARP) led the losers with a 25.1% decrease. Other notable movers included Biodexa Pharmaceuticals (BDRX), Tharimmune (THAR), Lexaria Bioscience (LEXX), and Mira Pharmaceuticals (MIRA) on the gainers' side, and Telesis Bio (TBIO), Altamira Therapeutics (CYTO), Universe Pharmaceuticals (UPC), Kazia Therapeutics (KZIA), and UpHealth (UPH) among the losers.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 5:30 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Mira Pharmaceuticals, TC BioPharm, Panbela Therapeutics, Estrella Immunopharma, Bio-Path Holdings, and MyMD Pharmaceuticals were among the gainers, with increases ranging from 7.14% to 9.2%. Conversely, Impel Pharmaceuticals, Avenue Therapeutics, Cyclacel Pharmaceuticals, Alaunos Therapeutics, Evoke Pharma, and Scholar Rock Holding were the losers, with their stock prices falling between 7.07% and 20.9%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 9:31 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. Inspire Veterinary (IVP) led the gainers with a 26.6% increase, while Axcella Health (AXLA) saw the largest decline among the losers, dropping 25.3%. Other notable gainers included Telesis Bio (TBIO), Femasys (FEMY), Assembly Biosciences (ASMB), MyMD Pharmaceuticals (MYMD), and Mira Pharmaceuticals (MIRA). On the losing side, Impel Pharmaceuticals (IMPL), Cardio Diagnostics Hldgs (CDIO), Alaunos Therapeutics (TCRT), Seelos Therapeutics (SEEL), and Heart Test Laboratories (HSCS) also saw their stock prices fall.

Portfolio Pulse from Benzinga Insights

November 23, 2023 | 9:31 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Impel Pharmaceuticals (IMPL) saw a dramatic increase of 141.4%, while Entrada Therapeutics (TRDA) faced a sharp decline of 33.1%. Other notable gainers include Conduit Pharmaceuticals (CDT), Telesis Bio (TBIO), AquaBounty Techs (AQB), PaxMedica (PXMD), and Seelos Therapeutics (SEEL). On the losing side, Alterity Therapeutics (ATHE), GRI Bio (GRI), Inspire Veterinary (IVP), Altamira Therapeutics (CYTO), and Mira Pharmaceuticals (MIRA) saw their stock prices fall.

Portfolio Pulse from Benzinga Insights

November 23, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.